Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of ziritaxestat (GLPG1690) in idiopathic pulmonary fibrosis
jRCT2080225268Phase 3Terminated
- Sponsor
- Galapagos NV
- Start
- Jul 2020
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ziritaxestat in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Galapagos NV. Started Jul 2020; status: terminated.
02
Drugs
ziritaxestat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2080225268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225268.